Soligenix (NASDAQ:SNGX) Lifted to Hold at ValuEngine

ValuEngine upgraded shares of Soligenix (NASDAQ:SNGX) from a sell rating to a hold rating in a research report sent to investors on Thursday, ValuEngine reports.

Separately, Maxim Group set a $25.00 price objective on shares of Aridis Pharmaceuticals and gave the company a buy rating in a report on Thursday, May 16th.

Shares of Soligenix stock opened at $1.14 on Thursday. Soligenix has a 1 year low of $0.65 and a 1 year high of $2.20. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.20 and a quick ratio of 2.20. The business’s fifty day simple moving average is $0.79.

Soligenix (NASDAQ:SNGX) last released its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.05. Soligenix had a negative net margin of 157.34% and a negative return on equity of 140.01%. The company had revenue of $1.10 million during the quarter, compared to analysts’ expectations of $1.30 million. As a group, equities analysts anticipate that Soligenix will post -0.49 earnings per share for the current fiscal year.

About Soligenix

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer.

Read More: Book Value Per Share – BVPS

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with's FREE daily email newsletter.